Impact of Concomitant Medication Administered at the Time of
Initiation of Nivolumab Therapy on Outcome in Non-small Cell
Lung Cancer

a 2020

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

SVATOŇ, M., M. ZEMANOVÁ, P. ZEMANOVÁ, P. KULTAN, O. FISCHER et. al.

Základní údaje

Originální název

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Autoři

SVATOŇ, M. (203 Česká republika), M. ZEMANOVÁ (203 Česká republika), P. ZEMANOVÁ (203 Česká republika), P. KULTAN (203 Česká republika), O. FISCHER (203 Česká republika), Jana SKŘIČKOVÁ (203 Česká republika, domácí), Lenka JAKUBÍKOVÁ (203 Česká republika, domácí), M. ČERNOVSKÁ (203 Česká republika), Michal HRNČIARIK (203 Česká republika), M. JIROUŠEK (203 Česká republika), J. KŘEJČÍ (203 Česká republika), D. KREJČÍ (203 Česká republika), O. BÍLEK (203 Česká republika), J. BLAŽEK (203 Česká republika), K. HURDÁLKOVÁ (203 Česká republika), M. BARINOVÁ (203 Česká republika) a B. MELICHAR (203 Česká republika)

Vydání

Anticancer Research,40 (4), pp.2209-2217, 2020

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30203 Respiratory systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.480

Kód RIV

RIV/00216224:14110/20:00115821

Organizační jednotka

Lékařská fakulta

ISSN

DOI

http://dx.doi.org/10.21873/anticanres.14182

UT WoS

000522734400050

Klíčová slova česky

Lung Diseases Interstitial | Carcinoma Non-Small-Cell Lung | Disease ILD

Klíčová slova anglicky

Lung Diseases Interstitial | Carcinoma Non-Small-Cell Lung | Disease ILD

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 5. 2022 12:25, RNDr. Pavel Šmerk, Ph.D.

Anotace

V originále

To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment. © 2020 International Institute of Anticancer Research. All rights reserved.

Citovat

SVATOŇ, M., M. ZEMANOVÁ, P. ZEMANOVÁ, P. KULTAN, O. FISCHER, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, M. ČERNOVSKÁ, Michal HRNČIARIK, M. JIROUŠEK, J. KŘEJČÍ, D. KREJČÍ, O. BÍLEK, J. BLAŽEK, K. HURDÁLKOVÁ, M. BARINOVÁ a B. MELICHAR. Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer. In Anticancer Research,40 (4), pp.2209-2217. 2020. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.14182.

@proceedings{1663023,
   author = {Svatoň, M. and Zemanová, M. and Zemanová, P. and Kultan, P. and Fischer, O. and Skřičková, Jana and Jakubíková, Lenka and Černovská, M. and Hrnčiarik, Michal and Jiroušek, M. and Křejčí, J. and Krejčí, D. and Bílek, O. and Blažek, J. and Hurdálková, K. and Barinová, M. and Melichar, B.},
   booktitle = {Anticancer Research,40 (4), pp.2209-2217},
   doi = {http://dx.doi.org/10.21873/anticanres.14182},
   keywords = {Lung Diseases Interstitial | Carcinoma Non-Small-Cell Lung | Disease ILD},
   language = {eng},
   title = {Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer},
   year = {2020}
}

TY  - CONF
ID  - 1663023
AU  - Svatoň, M. - Zemanová, M. - Zemanová, P. - Kultan, P. - Fischer, O. - Skřičková, Jana - Jakubíková, Lenka - Černovská, M. - Hrnčiarik, Michal - Jiroušek, M. - Křejčí, J. - Krejčí, D. - Bílek, O. - Blažek, J. - Hurdálková, K. - Barinová, M. - Melichar, B.
PY  - 2020
TI  - Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
KW  - Lung Diseases Interstitial | Carcinoma Non-Small-Cell Lung | Disease ILD
N2  - To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment. © 2020 International Institute of Anticancer Research. All rights reserved.
ER  -

SVATOŇ, M., M. ZEMANOVÁ, P. ZEMANOVÁ, P. KULTAN, O. FISCHER, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, M. ČERNOVSKÁ, Michal HRNČIARIK, M. JIROUŠEK, J. KŘEJČÍ, D. KREJČÍ, O. BÍLEK, J. BLAŽEK, K. HURDÁLKOVÁ, M. BARINOVÁ a B. MELICHAR. Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer. In \textit{Anticancer Research,40 (4), pp.2209-2217}. 2020. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.14182.

Podrobný výpis o publikaci